Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | CA4 | P22748 | 1/20 | 0.50 |
| ▸ | CA6 | P23280 | 1/20 | 0.50 |
| ▸ | CA7 | P43166 | 1/20 | 0.50 |
| ▸ | TPMT | P51580 | 1/20 | 0.50 |
| ▸ | CA9 | Q16790 | 1/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.50 |
| ▸ | CASP6 | P55212 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.49 |
| ▸ | THRA | P10827 | 1/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.48 |
| ▸ | WDR5 | P61964 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9623925 | 0.93 | POLB (0.55) | CA12CA1CA2CA4CA6 | |
| SCHEMBL2585353 | 0.92 | KDM4E (0.55) | KDM4EKMT2ACA12CA1CA2 | |
| SCHEMBL23792950 | 0.87 | TSHR (0.50) | KMT2ACA12CA1CA2CA4 | |
| SCHEMBL1436418 | 0.87 | POLB (0.64) | KDM4ECA12CA1CA2CA4 | |
| SCHEMBL25314236 | 0.86 | TDP1 (0.57) | KDM4EKMT2ACA12CA1CA2 | |
| SCHEMBL12492247 | 0.85 | THRA (0.56) | KMT2APOLBCASP6TSHRMRGPRX4 | |
| SCHEMBL12492815 | 0.85 | MRGPRX4 (0.50) | KDM4EPOLBCASP6TSHRMRGPRX4 | |
| SCHEMBL1665325 | 0.84 | TSHR (0.49) | KDM4EPOLBCASP6TSHRMRGPRX4 | |
| SCHEMBL7358447 | 0.84 | CA12 (0.69) | CA12CA1CA2CA4CA6 | |
| SCHEMBL6939685 | 0.84 | TSHR (0.71) | CA12CA1CA2CA4CA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230416228-A1 | AGENTS FOR THE TREATMENT OF DISEASES BY INHIBITION OF FOXO1 | THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEWYORK | 2023-12-28 | — | — | US | disclosed |
| EP-4217355-A1 | AGENTS FOR THE TREATMENT OF DISEASES BY INHIBITION OF FOXO1 | Forkhead Biotherapeutics, inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| WO-2022066938-A1 | AGENTS FOR THE TREATMENT OF DISEASES BY INHIBITION OF FOXO1 | FORKHEAD BIOTHERAPEUTICS, INC. (US) | 2022-03-31 | — | — | WO | disclosed |
| EP-2686325-B1 | MORPHOLINE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMA (US) | 2016-12-14 | — | — | EP | disclosed |
| EP-2686325-B1 | MORPHOLINE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMA (US) | 2016-12-14 | — | — | EP | disclosed |
| EP-2595989-B1 | HETEROCYCLIC CHROMENE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMA (US) | 2016-07-13 | — | — | EP | disclosed |
| EP-2595989-B1 | HETEROCYCLIC CHROMENE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMA (US) | 2016-07-13 | — | — | EP | disclosed |
| US-9365588-B2 | Benzoxazines as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-06-14 | — | — | US | disclosed |
| US-9365588-B2 | Benzoxazines as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-06-14 | — | — | US | disclosed |
| US-9365588-B2 | Benzoxazines as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2016-06-14 | — | — | US | disclosed |
| US-20120264749-A1 | MORPHOLINE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2012-10-18 | — | — | US | disclosed |
| US-20120264749-A1 | MORPHOLINE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2012-10-18 | — | — | US | disclosed |
| US-20120264749-A1 | MORPHOLINE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED | 2012-10-18 | — | — | US | disclosed |
| WO-2012125613-A1 | MORPHOLINE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-09-20 | — | — | WO | disclosed |
| WO-2012125613-A1 | MORPHOLINE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-09-20 | — | — | WO | disclosed |
| US-20110306607-A1 | HETEROCYCLIC CHROMENE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-12-15 | — | — | US | disclosed |
| US-20110306607-A1 | HETEROCYCLIC CHROMENE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-12-15 | — | — | US | disclosed |
| US-20110306607-A1 | HETEROCYCLIC CHROMENE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-12-15 | — | — | US | disclosed |
| WO-2011140425-A1 | HETEROCYCLIC CHROMENE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-11-10 | — | — | WO | disclosed |
| WO-2011140425-A1 | HETEROCYCLIC CHROMENE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230416228-A1 | AGENTS FOR THE TREATMENT OF DISEASES BY INHIBITION OF FOXO1 | FOXO1, FOXO3, GCKR | KDM4E 1362/4885KMT2A 1707/4885CA12 4667/4885 |
| US-20110306607-A1 | HETEROCYCLIC CHROMENE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | KCNJ2, TRPV1, KCNJ1 | KDM4E 2537/4885KMT2A 2425/4885CA12 3905/4885 |
| US-20120264749-A1 | MORPHOLINE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | KCNJ2, TRPM5, KCNQ1 | KDM4E 2462/4885KMT2A 1876/4885CA12 4475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.